Overview

506U78 in Treating Patients With Refractory Hematologic Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Cancer Institute (NCI)
Collaborator:
Children's Cancer Group
Treatments:
Cortisol succinate
Cytarabine
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Methotrexate
Criteria
Inclusion Criteria:

- Refractory or recurrent acute lymphocytic leukemia (ALL) or non-Hodgkin's lymphoma
(NHL) with bone marrow involvement (T-cell disease only)

- Isolated CNS relapse not eligible

- Performance status - Karnofsky 50-100%

- At least 8 weeks

- Bilirubin no greater than 1.5 mg/dL

- SGPT less than 5 times normal

- Creatinine normal for age

- Creatinine clearance or GFR at least 60 mL/min/1.73m2

- No severe uncontrolled infection

- No concurrent biologic therapy

- Recovered from toxic effects

- At least 6 weeks from administration of nitrosoureas

- No concurrent endocrine therapy

- At least 6 weeks from administration of craniospinal or hemi pelvic radiotherapy